Jean-François Formela focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.
He is chair of the board of IFM Therapeutics and serves on the boards of F-star, Kyn Therapeutics, Spero Therapeutics, and Translate Bio (formerly RaNA Therapeutics), which he co-founded.
Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Eli Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM, acquired by Fresenius Medical) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Eli Lilly). He also was an investor in Achillion (NASDAQ: ACHN), Annovation Biopharma (acquired by The Medicines Company), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).
Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.
Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art.
He received his M.D. from Paris University School of Medicine, and his M.B.A. from Columbia University.
How do I contact Jean-Francois Formela?
Has Jean-Francois Formela been buying or selling shares of Intellia Therapeutics?
Jean-Francois Formela has not been actively trading shares of Intellia Therapeutics during the last ninety days. Most recently, Jean Francois Formela sold 553,376 shares of the business's stock in a transaction on Monday, June 28th. The shares were sold at an average price of $132.73, for a transaction totalling $73,449,596.48. Learn More on Jean-Francois Formela's trading history.
Who are Intellia Therapeutics' active insiders?
Are insiders buying or selling shares of Intellia Therapeutics?
In the last year, insiders at the sold shares 10 times. They sold a total of 42,760 shares worth more than $1,368,462.19. The most recent insider tranaction occured on March, 4th when EVP James Basta sold 2,297 shares worth more than $75,778.03. Insiders at Intellia Therapeutics own 3.0% of the company.
Learn More about insider trades at Intellia Therapeutics. Information on this page was last updated on 3/4/2024.
